Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: SUMMARY:
Aromatase inhibitors together with an antiandrogen appear to be a very promising treatment for FMPP. Further longer-term studies with letrozole are needed in MAS. The prevalence of vertebral deformities should be evaluated prospectively in patients treated with aromatase inhibitors. Adult height data are still lacking in pediatric patients treated with aromatase inhibitors. Two years of therapy in pre and peripubertal short boys does not appear to increase adult height. Hemogram, lipids, and bone density should be periodically assessed in treated patients. Further controlled studies are needed to demonstrate safety and efficacy of aromatase inhibitors in pediatric patients.
|
Authors | Alicia Diaz-Thomas, Dorothy Shulman |
Journal | Current opinion in pediatrics
(Curr Opin Pediatr)
Vol. 22
Issue 4
Pg. 501-7
(Aug 2010)
ISSN: 1531-698X [Electronic] United States |
PMID | 20489637
(Publication Type: Journal Article, Review)
|
Chemical References |
- Aromatase Inhibitors
- Aromatase
|
Topics |
- Adolescent
- Adolescent Development
(drug effects)
- Aromatase
(blood)
- Aromatase Inhibitors
(therapeutic use)
- Child
- Child Development
(drug effects)
- Female
- Growth Disorders
(drug therapy, enzymology)
- Humans
- Male
- Prognosis
- Puberty, Precocious
(enzymology, prevention & control)
|